AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1829078 — intervention group
Group type: COMPARATOR
Intervention: Tri-antibiotic regimen (teicoplanin, ceftriaxone, amikacin) when fever occurred (arm B)
Number of subjects: 71
Study 6871920 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release quinidine gluconate
Number of subjects: 16
Study 6871920 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release quinidine sulfate
Number of subjects: 16
Study 29806538 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1158061 (30 mg at 14-day interval)
Number of subjects: 29
Study 29806538 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1158061 (60 mg at 28-day interval)
Number of subjects: 29
Study 29806538 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1158061 (90 mg at 14-day interval)
Number of subjects: 29
Study 29806538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29806538 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1158061
Number of subjects: 29
Study 27894822 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTdp + Standard Care (SC)
Number of subjects: 29
Study 27894822 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 29
Study 26446239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab in combination with docetaxel
Number of subjects: 1253
Study 26446239 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with docetaxel
Number of subjects: 1253
Study 23258932 — intervention group
Group type: EXPERIMENTAL
Intervention: Three individualized nutritional counselling visits by a registered dietitian complemented with three follow-up visits by general practitioners
Number of subjects: 152
Study 23258932 — intervention group
Group type: COMPARATOR
Intervention: Three follow-up visits by general practitioners alone
Number of subjects: 152
Study 21251337 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity
Number of subjects: 1359
Study 21251337 — intervention group
Group type: EXPERIMENTAL
Intervention: TV viewing
Number of subjects: 1359
Study 19302639 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline washout (30 ml saline)
Number of subjects: 70
Study 19302639 — intervention group
Group type: COMPARATOR
Intervention: Control (no washout)
Number of subjects: 70
Study 17969888 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM therapy according to syndrome differentiation combined with Western medicine
Number of subjects: 279
Study 17969888 — intervention group
Group type: COMPARATOR
Intervention: Western medicine by staging
Number of subjects: 279
Study 12904089 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1094
Study 10858688 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered glycerine suppository
Number of subjects: 131
Study 9345330 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 30
Study 9345330 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 8384949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure of -20 mmHg in subgroup B (10 patients)
Number of subjects: 24
Study 8384949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure of -20 mmHg in subgroup A (8 patients)
Number of subjects: 24
Study 8384949 — intervention group
Group type: EXPERIMENTAL
Intervention: Second bout of lower-body negative pressure in subgroup B (7 patients)
Number of subjects: 24
Study 3528853 — intervention group
Group type: EXPERIMENTAL
Intervention: Human surfactant
Number of subjects: 60
Study 3528853 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 31282698 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (suggestion of cognitive enhancement)
Number of subjects: 2
Study 31282698 — intervention group
Group type: COMPARATOR
Intervention: Control group (no suggestion of cognitive enhancement)
Number of subjects: 2
Study 30169547 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg Nimesulide immediate, intermediate and slow release tablets
Number of subjects: 0
Study 27107395 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover balloon occlusion technique (CBOT)
Number of subjects: 98
Study 27107395 — intervention group
Group type: COMPARATOR
Intervention: Control (no CBOT)
Number of subjects: 98
Study 24885645 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy-based gait training supported by withdrawal reflex stimulation
Number of subjects: 0
Study 24885645 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy-based gait training alone (Control)
Number of subjects: 0
Study 22717544 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 1280
Study 22717544 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 1280
Study 22717544 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-varying Cornell product
Number of subjects: 1280
Study 20847699 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc or Lopinavir/Ritonavir (4 weeks)
Number of subjects: 10
Study 20847699 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (4 weeks)
Number of subjects: 10
Study 19491469 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic lesional surgery
Number of subjects: 11
Study 19491469 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 11
Study 15844733 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU of recombinant FSH (Puregon)
Number of subjects: 192
Study 15844733 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of recombinant FSH (Puregon)
Number of subjects: 192
Study 12067170 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 55
Study 12067170 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 55
Study 12067170 — intervention group
Group type: EXPERIMENTAL
Intervention: EACA
Number of subjects: 55
Study 10651671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (75 or 100 microg) combined with 5 mg of isobaric bupivacaine
Number of subjects: 34
Study 10651671 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous saline solution (control group)
Number of subjects: 34
Study 10651671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine combined with bupivacaine
Number of subjects: 34
Study 8878142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplements (OS)
Number of subjects: 3
Study 8878142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric feeding (NG)
Number of subjects: 3
Study 8878142 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 3
Study 2004961 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D treatment planning (19.8 Gy boost of a total 70.2 Gy treatment schedule)
Number of subjects: 15
Study 2004961 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D treatment planning
Number of subjects: 15
Study 2004961 — intervention group
Group type: COMPARATOR
Intervention: 2D treatment planning
Number of subjects: 15
Study 7064681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 270
Study 7064681 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl penicillin
Number of subjects: 270
Study 7064681 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 270
Study 30797256 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride (SnF2) dentifrice with zinc phosphate (Colgate TotalSF)
Number of subjects: 135
Study 30797256 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF2) with zinc lactate dentifrice
Number of subjects: 135
Study 30797256 — intervention group
Group type: COMPARATOR
Intervention: Control fluoride dentifrice
Number of subjects: 135
Study 30797256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SnF2 dentifrices
Number of subjects: 135
Study 30797256 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice (SnF2 with zinc phosphate)
Number of subjects: 135
Study 29597198 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (12 weeks)
Number of subjects: 20
Study 29597198 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (inactive group)
Number of subjects: 20
Study 25398398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan-enriched embryo transfer medium
Number of subjects: 581
Study 23758092 — intervention group
Group type: EXPERIMENTAL
Intervention: ceramic‐ceramic (Yttria‐stabilized zirconia core, pressable fluorapatite glass‐ceramic)
Number of subjects: 55
Study 23758092 — intervention group
Group type: EXPERIMENTAL
Intervention: metal‐ceramic (palladium‐based noble alloy with press‐on leucite‐reinforced glass‐ceramic veneer)
Number of subjects: 55
Study 22789677 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity (measured by FN400 ERP component) in Experiment 1
Number of subjects: 0
Study 22789677 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity (measured by FN400 ERP component) in Experiment 2
Number of subjects: 0
Study 22789677 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity (measured by FN400 ERP component) in Experiment 3
Number of subjects: 0
Study 21058478 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needle therapy
Number of subjects: 54
Study 21058478 — intervention group
Group type: COMPARATOR
Intervention: Filiform needling (common needling technique)
Number of subjects: 54
Study 17711926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761)
Number of subjects: 0
Study 17711926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15848557 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 mg of oral enteric-coated mycophenolate sodium (E-MPS)
Number of subjects: 12
Study 12669777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg via 2-hour intravenous infusion every 3 to 4 weeks for 12 months
Number of subjects: 9
Study 12669777 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg via 15-minute intravenous infusion every 3 to 4 weeks for 12 months
Number of subjects: 9
Study 12669777 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 8 mg via 15-minute intravenous infusion every 3 to 4 weeks for 12 months
Number of subjects: 9
Study 12669777 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9
Study 12080961 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (microwave thermotherapy with the Dornier Urowave)
Number of subjects: 220
Study 12080961 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 220
Study 12080961 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 220
Study 12080961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 220
Study 7667816 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin, 20 mg per day for one month
Number of subjects: 30
Study 7667816 — intervention group
Group type: COMPARATOR
Intervention: Moroxydine chloride, 1200 mg per day for one month
Number of subjects: 30
Study 2730099 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 4
Study 2730099 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 4
Study 2730099 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 4
Study 6969625 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral BCG immunotherapy
Number of subjects: 39
Study 6969625 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 39
Study 31256647 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly crosslinked polyethylene (XLP)
Number of subjects: 245
Study 31256647 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene (SP)
Number of subjects: 245
Study 31256647 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 245
Study 29099680 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT with 100 mW power output per diode (500 mW total)
Number of subjects: 28
Study 29099680 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT with 200 mW power output per diode
Number of subjects: 28
Study 29099680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 25503625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 29
Study 25503625 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (diphenhydramine)
Number of subjects: 29
Study 23806395 — intervention group
Group type: EXPERIMENTAL
Intervention: V-Loc sutures
Number of subjects: 80
Study 23806395 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin sutures
Number of subjects: 80
Study 21702128 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (alpha7 nAchR agonist and 5‐HT3 receptor antagonist)
Number of subjects: 0
Study 21702128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18643849 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour patch application of PD P 506 A
Number of subjects: 140
Study 18643849 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour patch application of PD P 506 A
Number of subjects: 140
Study 18643849 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour patch application of PD P 506 A
Number of subjects: 140
Study 18643849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-hour patch application of PD P 506 A
Number of subjects: 140
Study 17536077 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for factors affecting glycemia (age, sex, education, marital status, blood pressure, adiposity, hematocrit, fasting and post-glucose load glucose levels, glucose area under the curve, beta-cell function, insulin resistance)
Number of subjects: 3819
Study 17536077 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (comparison among racial and ethnic groups)
Number of subjects: 3819
Study 17042145 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (2 sprays per nostril twice daily)
Number of subjects: 360
Study 17042145 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine (10-mg tablets once daily)
Number of subjects: 360
Study 17042145 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 360
Study 12706362 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy boost
Number of subjects: 5569
Study 12706362 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost dose for patients ≤40 years
Number of subjects: 5569
Study 12706362 — intervention group
Group type: COMPARATOR
Intervention: No boost
Number of subjects: 5569
Study 12706362 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a factor
Number of subjects: 5569
Study 10589637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of levobupivacaine 0.25% and morphine 0.005%
Number of subjects: 0
Study 10589637 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.25%
Number of subjects: 0
Study 10589637 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.005%
Number of subjects: 0
Study 10163386 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (HDE) - 5, 10, and 15 mg boluses to a total dose of 30 mg
Number of subjects: 1174
Study 10163386 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (SDE) - 1.0 mg boluses to a maximum dose of 4 mg
Number of subjects: 1174
Study 1678965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg once a day)
Number of subjects: 24
Study 1678965 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (10 mg three times a day)
Number of subjects: 24
Study 1678965 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Bisoprolol and Propranolol
Number of subjects: 24
Study 1678965 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 24
Study 1678965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 24
Study 6351901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atenolol 25 mg twice daily
Number of subjects: 24
Study 6351901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atenolol 50 mg once daily
Number of subjects: 24
Study 6351901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atenolol 100 mg once daily
Number of subjects: 24
Study 6351901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29355679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 241
Study 29355679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks (q2w)
Number of subjects: 241
Study 29355679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 26618282 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide plus diet
Number of subjects: 165
Study 26618282 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus diet
Number of subjects: 165
Study 24881610 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1%
Number of subjects: 76
Study 24881610 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 76
Study 23739977 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition Trials (RTs)
Number of subjects: 0
Study 23739977 — intervention group
Group type: COMPARATOR
Intervention: Alternation Trials (ATs)
Number of subjects: 0
Study 23739977 — intervention group
Group type: COMPARATOR
Intervention: Repetition Blocks (RBs)
Number of subjects: 0
Study 23739977 — intervention group
Group type: COMPARATOR
Intervention: Alternation Blocks (ABs)
Number of subjects: 0
Study 20142520 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with verteporfin
Number of subjects: 54
Study 20142520 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (LT)
Number of subjects: 54
Study 20142520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 54
Study 18165394 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mcg E2
Number of subjects: 230
Study 18165394 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mcg E2
Number of subjects: 230
Study 18165394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 16364826 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 82
Study 16364826 — intervention group
Group type: COMPARATOR
Intervention: carvedilol 25 mg
Number of subjects: 82
Study 12463664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration
Number of subjects: 61
Study 12463664 — intervention group
Group type: COMPARATOR
Intervention: Arthrotomy
Number of subjects: 61
Study 10504599 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐blind intradermal provocation/neutralization skin tests to food antigens
Number of subjects: 10
Study 10504599 — intervention group
Group type: EXPERIMENTAL
Intervention: Strobovideolaryngoscopy
Number of subjects: 10
Study 10504599 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐blind measurements of signs and symptoms, digital audio recordings for perceptual and acoustic analysis, aerodynamic laryngeal airflow and resistance measurements
Number of subjects: 10
Study 8947786 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback (n = 40)
Number of subjects: 60
Study 8947786 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-out group (n = 19)
Number of subjects: 60
Study 8947786 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-in group (n = 18)
Number of subjects: 60
Study 8947786 — intervention group
Group type: COMPARATOR
Intervention: Neutral feedback (n = 20)
Number of subjects: 60
Study 1848721 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml 1% mepivacaine with pH raised to 7.25 by adding 4 ml 8.4% NaHCO3
Number of subjects: 60
Study 1848721 — intervention group
Group type: COMPARATOR
Intervention: 40 ml commercially prepared 1% mepivacaine hydrochloride solution containing 4 ml 0.9% NaCl (pH 6.0)
Number of subjects: 60
Study 6802875 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2‐65% O2 inhalations
Number of subjects: 12
Study 6802875 — intervention group
Group type: COMPARATOR
Intervention: Compressed air (placebo control)
Number of subjects: 12
Study 31889433 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed hypoxic dose protocol (LHTLH)
Number of subjects: 10
Study 31103108 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (8 weeks, 1 hour a day, 5 days a week)
Number of subjects: 60
Study 31103108 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group (normal routine)
Number of subjects: 60
Study 28171856 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-assisted bronchoscopy
Number of subjects: 105
Study 28171856 — intervention group
Group type: COMPARATOR
Intervention: Standard nasal bronchoscopy
Number of subjects: 105
Study 25936635 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (3.3 ± 3.0 mg/kg/day)
Number of subjects: 69
Study 25936635 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 69
Study 25936635 — intervention group
Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 69
Study 24005547 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality goggles
Number of subjects: 34
Study 24005547 — intervention group
Group type: COMPARATOR
Intervention: Memory from the lecture (Control)
Number of subjects: 34
Study 21874537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 178
Study 21874537 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40-80 mg
Number of subjects: 178
Study 19153939 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo-Alpha-Acetylmethadol (LAAM)
Number of subjects: 84
Study 19153939 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 84
Study 17934877 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with agalsidase alfa infusions for > or = 18 months
Number of subjects: 47
Study 17934877 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment with head impulse testing (HIT)
Number of subjects: 47
Study 17934877 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment with pure tone audiometry (PTA)
Number of subjects: 47